HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer

Kubota, Tetsushi; Kuroda, Shigetoshi; Kanaya, Nobuhiko; Morihiro, Toshiaki; Aoyama, Katsuyuki; Kakiuchi, Yoshihiko; Kikuchi, Shinichi; Nishizaki, Masahiko; Kagawa, Shunsuke; Tazawa, Hiroshi; Fujiwara, Toshiyoshi

doi:10.1016/j.nano.2018.05.019

Cited by 63 publications

(40 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While most conjugates in the literature use some variation of this amide bond formation involving lysines on the antibody, a PEG linker terminated in a hydrazide can be used, which allows for the cross-linking of AuNPs with carboxylic acids on the surface of antibodies. 73 This chemistry, while utilising different residues on the antibody is still completely random and may lead to even more variations as there are on average more carboxylic acids present on antibodies than amines. 74 While antibodies display high affinity towards their target, this affinity relies on the antigen binding sites remaining nonfunctionalised and unhindered.…”

Section: Igg Antibodiesmentioning

confidence: 99%

Active targeting of gold nanoparticles as cancer therapeutics

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Igg Antibodiesmentioning

confidence: 99%

Active targeting of gold nanoparticles as cancer therapeutics

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Subcutaneous tumors were formed after subcutaneous injection of MKN1-Luc, KATO III, and MKN45-Luc cells. Previous reports have shown that N87, NUGC4 and OCUM-1 can form subcutaneous tumors in nude mice (14)(15)(16)(17)(18).…”

Section: Resultsmentioning

confidence: 98%

Establishment of Peritoneal and Hepatic Metastasis Mouse Xenograft Models Using Gastric Cancer Cell Lines

Miwa

Kanda

Umeda

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: Establishment of mouse xenograft models is necessary for oncological research and depends on the characteristics of the cell lines and the immune system of the host. In this study, we describe the development of mouse xenograft models using human gastric cancer (GC) cell lines. Materials and Methods: MKN1 stably-expressing luciferase (MKN1-Luc), N87, KATO III, MKN45 stably-expressing luciferase (MKN45-Luc), NUGC4, and OCUM-1 human GC cell lines were injected intraperitoneally into mice to establish peritoneal metastasis models. MKN45-Luc were injected into subcutaneously implanted spleen, and MKN1-Luc and MKN45-Luc were injected directly into the portal veins of mice for the establishment of hepatic metastasis models. Results: Peritoneal metastasis was formed after implantation of MKN1-Luc, N87, KATO III, MKN45-Luc, and NUGC4 in nude mice, but not formed in OCUM-1 even in NOD/SCID mice. After intrasplenic injection of MKN45-Luc, we found no hepatic metastasis formation. We identified hepatic metastasis formation after direct injection of MKN45-Luc and MKN1-Luc into the portal veins of NOD/SCID mice. Conclusion: Peritoneal and hepatic metastasis mouse xenograft models were successfully established using several human GC cell lines. Gastric cancer (GC) is the fourth leading cause of cancerrelated death worldwide (1). Perioperative adjuvant therapy has improved prognosis to a certain degree (2-4). However, Materials and Methods Cell lines and cell culture. MKN1 cells stably expressing luciferase (MKN1-Luc), MKN45 cells stably expressing luciferase (MKN45-Luc), NUGC4, and OCUM-1 were obtained from the Japanese Collection of Research Bio Resources Cell Bank (JCRB) (Osaka, Japan). N87 and KATO III cell lines were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells were incubated at 37˚C with 5% CO 2 in the recommended medium supplemented with 10% fetal bovine serum. The characteristics of the gastric cancer cell lines are listed in Table I.

show abstract

“…For example, Sharma et al (2008) have chemically conjugated anti-HER2 to CpG, which has led to tumor eradication and induction of protective memory when combined with anti-GITR immunotherapy. In addition, tumor-targeting antibodies have been conjugated to material surfaces, such as nanoparticles (Kubota et al, 2018) or liposomes (Espelin et al, 2016), to confer them the ability to target tumors. Interestingly, biological cell-based materials can be similarly engineered; for instance, in the context of chimeric antigen receptor (CAR)-T cell therapies, patient-derived T lymphocytes are transduced with a modified TCR that comprises a scFv fragment recognizing a specific cancer antigen (Jackson et al, 2016).…”

Section: Targeting the Cancer Cell Surface (Figure 4a)mentioning

confidence: 99%

Engineering Targeting Materials for Therapeutic Cancer Vaccines

Briquez

Hauert

Titta³

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Therapeutic cancer vaccines constitute a valuable tool to educate the immune system to fight tumors and prevent cancer relapse. Nevertheless, the number of cancer vaccines in the clinic remains very limited to date, highlighting the need for further technology development. Recently, cancer vaccines have been improved by the use of materials, which can strongly enhance their intrinsic properties and biodistribution profile. Moreover, vaccine efficacy and safety can be substantially modulated through selection of the site at which they are delivered, which fosters the engineering of materials capable of targeting cancer vaccines to specific relevant sites, such as within the tumor or within lymphoid organs, to further optimize their immunotherapeutic effects. In this review, we aim to give the reader an overview of principles and current strategies to engineer therapeutic cancer vaccines, with a particular focus on the use of sitespecific targeting materials. We will first recall the goal of therapeutic cancer vaccination and the type of immune responses sought upon vaccination, before detailing key components of cancer vaccines. We will then present how materials can be engineered to enhance the vaccine's pharmacokinetic and pharmacodynamic properties. Finally, we will discuss the rationale for site-specific targeting of cancer vaccines and provide examples of current targeting technologies.

show abstract

HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer

Cited by 63 publications

References 39 publications

Active targeting of gold nanoparticles as cancer therapeutics

Active targeting of gold nanoparticles as cancer therapeutics

Establishment of Peritoneal and Hepatic Metastasis Mouse Xenograft Models Using Gastric Cancer Cell Lines

Engineering Targeting Materials for Therapeutic Cancer Vaccines

Contact Info

Product

Resources

About